REGENXBIO (RGNX) to Release Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect REGENXBIO to post earnings of ($1.13) per share and revenue of $40.87 million for the quarter.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million during the quarter, compared to analysts' expectations of $105.35 million. REGENXBIO had a negative return on equity of 53.29% and a negative net margin of 100.62%. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

REGENXBIO Trading Down 3.8%

Shares of RGNX stock traded down $0.32 during trading hours on Friday, hitting $8.19. 539,624 shares of the company's stock were exchanged, compared to its average volume of 992,754. The company has a market capitalization of $410.81 million, a PE ratio of -2.63 and a beta of 1.06. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $13.48. The business's 50 day simple moving average is $8.91 and its 200-day simple moving average is $8.00.

Insider Buying and Selling

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director owned 475,103 shares of the company's stock, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 12.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On REGENXBIO

An institutional investor recently raised its position in REGENXBIO stock. AQR Capital Management LLC increased its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 2,247.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 620,595 shares of the biotechnology company's stock after purchasing an additional 594,161 shares during the quarter. AQR Capital Management LLC owned approximately 1.24% of REGENXBIO worth $4,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RGNX has been the topic of a number of analyst reports. Chardan Capital reiterated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Monday, June 9th. The Goldman Sachs Group reduced their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.